FDA clearance is a critical regulatory milestone that can significantly impact a company's product portfolio and market position. For Baxter, this approval not only enhances its infusion therapy offerings but also demonstrates its commitment to innovation and patient care. This is likely to be viewed positively by investors and could lead to increased investor confidence in Baxter's growth trajectory, potentially driving up the stock price in the short term.